Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium

Nicholas Feasey; Raheelah Ahmad; Elizabeth Ashley; Rifat Atun; Kate S Baker; Francesca Chiari; H Rogier van Doorn; Alison Holmes; Timothy Jinks; Andrew Jermy; Jyoti Joshi; Souha S Kanj; Matt King; Direk Limmathurotsakul; Janet Midega; Mirfin Mpundu; Jamie Nunn; Iruka N Okeke; Stuart Reid; Dawn Sievert; Paul Turner; Kamini Walia; Sharon J Peacock

doi:10.12688/wellcomeopenres.23494.1

Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium

Wellcome Open Res. 2025 Jan 13:10:5. doi: 10.12688/wellcomeopenres.23494.1. eCollection 2025.

Authors

Nicholas Feasey^{1

2}, Raheelah Ahmad^{3

4

5}, Elizabeth Ashley⁶, Rifat Atun⁷, Kate S Baker^{8

9}, Francesca Chiari¹⁰, H Rogier van Doorn^{6

11}, Alison Holmes³, Timothy Jinks¹⁰, Andrew Jermy¹², Jyoti Joshi¹³, Souha S Kanj¹⁴, Matt King¹⁵, Direk Limmathurotsakul¹⁶, Janet Midega¹⁰, Mirfin Mpundu¹⁷, Jamie Nunn¹⁸, Iruka N Okeke¹⁹, Stuart Reid²⁰, Dawn Sievert²¹, Paul Turner^{6

22}, Kamini Walia²³, Sharon J Peacock²⁴

Affiliations

¹ Department of Clinical Sciences,, Liverpool School of Tropical Medicine, Liverpool, UK.
² University of St Andrews School of Medicine, St Andrews, Scotland, UK.
³ NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
⁴ Department of Health Services Research and Management, University of London, London, England, UK.
⁵ Institute of Business and Health Management Dow University of Health Sciences, Karachi, Pakistan.
⁶ University of Oxford Nuffield Department of Medicine, Oxford, England, UK.
⁷ Harvard School of Public Health, Boston, Massachusetts, USA.
⁸ Genetics, University of Cambridge, Cambridge, UK.
⁹ University of Liverpool Institute of Infection Veterinary and Ecological Sciences, Neston, England, UK.
¹⁰ Drug resistant infections Priority Programme, Wellcome Trust, London, UK.
¹¹ Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
¹² Germinate, Germinate Science Consulting Ltd, Suffolk, UK.
¹³ International Centre for AMR Solutions, Copenhagen, Denmark.
¹⁴ Division of Infectious Diseases, Internal Medicine Department, and Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Lebanon.
¹⁵ ARCTA solutions Ltd, Hampshire, UK.
¹⁶ Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Bangkok, Thailand.
¹⁷ ReAct Africa, Lusaka, Zambia.
¹⁸ London School of Hygiene & Tropical Medicine, University of London, London, England, UK.
¹⁹ Department of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Oyo, Nigeria.
²⁰ The Royal Veterinary College, London, England, UK.
²¹ Antimicrobial Resistance Coordination and Strategy Unit, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atanta, Georgia, USA.
²² Cambodia Oxford Medical Research Unit, Siem Reap, Cambodia.
²³ Indian Council of Medical Research, New Delhi, Delhi, India.
²⁴ Medicine, University of Cambridge, Cambridge, UK.

Abstract

The increasing threat from infection with drug-resistant pathogens is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform policy and change the way countries track, share, and analyse data relating to drug-resistant infections, by defining knowledge gaps and identifying barriers to the delivery of global surveillance. SEDRIC delivers its aims through discussions and analyses by world-leading scientists that result in recommendations and advocacy to Wellcome and others. As a result, SEDRIC has made key contributions in furthering global and national actions. Here, we look back at the work of the consortium between 2018-2024, highlighting notable successes. We provide specific examples where technical analyses and recommendations have helped to inform policy and funding priorities that will have real-world impact on the surveillance and epidemiology of infections with drug-resistant pathogens.

Keywords: Antimicrobial resistance; surveillance.

Plain language summary

The increasing threat from infections that cannot be treated with medicines, so called drug resistant infections, is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform policy and change the way countries track, share, and analyse data relating to drug-resistant infections, by defining knowledge gaps and identifying barriers to the delivery of global surveillance. SEDRIC delivers its aims through discussions and analyses by world-leading scientists that result in recommendations and advocacy to Wellcome and others. As a result, SEDRIC has made key contributions in furthering global and national actions. Here, we look back at the work of the consortium between 2018-2024, highlighting notable successes. We provide specific examples where technical analyses and recommendations have helped to inform policy and funding priorities that will have real-world impact on the surveillance and of infections with pathogens that are becoming difficult or impossible to treat.

Grants and funding

WT_/Wellcome Trust/United Kingdom